CA2275425C - Aminoindan derivatives - Google Patents
Aminoindan derivatives Download PDFInfo
- Publication number
- CA2275425C CA2275425C CA002275425A CA2275425A CA2275425C CA 2275425 C CA2275425 C CA 2275425C CA 002275425 A CA002275425 A CA 002275425A CA 2275425 A CA2275425 A CA 2275425A CA 2275425 C CA2275425 C CA 2275425C
- Authority
- CA
- Canada
- Prior art keywords
- compound
- pharmaceutical composition
- therapeutically effective
- effective amount
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- XJEVHMGJSYVQBQ-UHFFFAOYSA-N 2,3-dihydro-1h-inden-1-amine Chemical class C1=CC=C2C(N)CCC2=C1 XJEVHMGJSYVQBQ-UHFFFAOYSA-N 0.000 title description 12
- 150000001875 compounds Chemical class 0.000 claims abstract description 157
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 47
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 38
- 206010012289 Dementia Diseases 0.000 claims abstract description 27
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 26
- 239000001257 hydrogen Substances 0.000 claims abstract description 25
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 claims abstract description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 19
- 239000003937 drug carrier Substances 0.000 claims abstract description 16
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 16
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims abstract description 15
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims abstract description 13
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims abstract description 13
- 208000000323 Tourette Syndrome Diseases 0.000 claims abstract description 11
- 208000016620 Tourette disease Diseases 0.000 claims abstract description 11
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims abstract description 11
- 230000006735 deficit Effects 0.000 claims abstract description 9
- 208000013403 hyperactivity Diseases 0.000 claims abstract description 9
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims abstract description 5
- 206010039966 Senile dementia Diseases 0.000 claims abstract description 5
- 125000005843 halogen group Chemical group 0.000 claims abstract description 5
- 208000009829 Lewy Body Disease Diseases 0.000 claims abstract description 4
- 201000002832 Lewy body dementia Diseases 0.000 claims abstract description 4
- 201000004810 Vascular dementia Diseases 0.000 claims abstract description 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract description 4
- 125000003118 aryl group Chemical group 0.000 claims abstract description 4
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims abstract 2
- 238000011282 treatment Methods 0.000 claims description 39
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 24
- 230000006378 damage Effects 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 23
- 230000000694 effects Effects 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 23
- 208000035475 disorder Diseases 0.000 claims description 18
- 239000007787 solid Substances 0.000 claims description 18
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 16
- -1 ethyl propargyl Chemical group 0.000 claims description 15
- 208000014674 injury Diseases 0.000 claims description 15
- 230000005764 inhibitory process Effects 0.000 claims description 13
- 206010021143 Hypoxia Diseases 0.000 claims description 12
- 102000010909 Monoamine Oxidase Human genes 0.000 claims description 12
- 108010062431 Monoamine oxidase Proteins 0.000 claims description 12
- 229910052799 carbon Inorganic materials 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 208000026139 Memory disease Diseases 0.000 claims description 11
- 208000027418 Wounds and injury Diseases 0.000 claims description 11
- 210000004556 brain Anatomy 0.000 claims description 11
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 9
- 208000020401 Depressive disease Diseases 0.000 claims description 9
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 9
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical group C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 claims description 9
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 8
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 8
- 230000007954 hypoxia Effects 0.000 claims description 8
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 206010036631 Presenile dementia Diseases 0.000 claims description 4
- 230000000302 ischemic effect Effects 0.000 claims description 4
- 230000000750 progressive effect Effects 0.000 claims description 4
- 229940095064 tartrate Drugs 0.000 claims description 4
- 230000008733 trauma Effects 0.000 claims description 4
- 206010002660 Anoxia Diseases 0.000 claims description 3
- 241000976983 Anoxia Species 0.000 claims description 3
- 206010019196 Head injury Diseases 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 230000007953 anoxia Effects 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 230000004770 neurodegeneration Effects 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- 231100000189 neurotoxic Toxicity 0.000 claims description 3
- 230000002887 neurotoxic effect Effects 0.000 claims description 3
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 3
- 230000003068 static effect Effects 0.000 claims description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 210000003169 central nervous system Anatomy 0.000 claims 4
- 210000001428 peripheral nervous system Anatomy 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 abstract description 23
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 46
- 241000699670 Mus sp. Species 0.000 description 31
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 20
- 239000000243 solution Substances 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 18
- 229940079593 drug Drugs 0.000 description 18
- 239000011780 sodium chloride Substances 0.000 description 18
- 238000012360 testing method Methods 0.000 description 16
- 241000700159 Rattus Species 0.000 description 15
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 14
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 14
- 238000000034 method Methods 0.000 description 13
- 102000012440 Acetylcholinesterase Human genes 0.000 description 11
- 108010022752 Acetylcholinesterase Proteins 0.000 description 11
- 229940022698 acetylcholinesterase Drugs 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 10
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 10
- 208000018652 Closed Head injury Diseases 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 208000030886 Traumatic Brain injury Diseases 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 210000003414 extremity Anatomy 0.000 description 8
- 230000011514 reflex Effects 0.000 description 8
- PKDBCJSWQUOKDO-UHFFFAOYSA-M 2,3,5-triphenyltetrazolium chloride Chemical compound [Cl-].C1=CC=CC=C1C(N=[N+]1C=2C=CC=CC=2)=NN1C1=CC=CC=C1 PKDBCJSWQUOKDO-UHFFFAOYSA-M 0.000 description 7
- 206010008089 Cerebral artery occlusion Diseases 0.000 description 7
- 150000002431 hydrogen Chemical group 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 201000007309 middle cerebral artery infarction Diseases 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 6
- 229960004373 acetylcholine Drugs 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 238000006722 reduction reaction Methods 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 210000003141 lower extremity Anatomy 0.000 description 5
- 230000000926 neurological effect Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 5
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 4
- 102100028661 Amine oxidase [flavin-containing] A Human genes 0.000 description 4
- 101710185917 Amine oxidase [flavin-containing] A Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- 238000012347 Morris Water Maze Methods 0.000 description 4
- 239000007832 Na2SO4 Substances 0.000 description 4
- PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 4
- 230000021235 carbamoylation Effects 0.000 description 4
- 125000001309 chloro group Chemical group Cl* 0.000 description 4
- 229940125961 compound 24 Drugs 0.000 description 4
- 229940125846 compound 25 Drugs 0.000 description 4
- 230000017858 demethylation Effects 0.000 description 4
- 238000010520 demethylation reaction Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 4
- 210000003194 forelimb Anatomy 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 4
- 229960001697 physostigmine Drugs 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- JRZGPXSSNPTNMA-UHFFFAOYSA-N 1,2,3,4-tetrahydronaphthalen-1-amine Chemical class C1=CC=C2C(N)CCCC2=C1 JRZGPXSSNPTNMA-UHFFFAOYSA-N 0.000 description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 3
- MOUPGBDOLGDVNW-UHFFFAOYSA-N 3-amino-2,3-dihydro-1h-inden-5-ol Chemical compound C1=C(O)C=C2C(N)CCC2=C1 MOUPGBDOLGDVNW-UHFFFAOYSA-N 0.000 description 3
- 102100028116 Amine oxidase [flavin-containing] B Human genes 0.000 description 3
- 101710185931 Amine oxidase [flavin-containing] B Proteins 0.000 description 3
- 108090000371 Esterases Proteins 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 206010061216 Infarction Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000452413 Sabra Species 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- 230000007574 infarction Effects 0.000 description 3
- 230000007659 motor function Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 238000006268 reductive amination reaction Methods 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 2
- GFFIJCYHQYHUHB-UHFFFAOYSA-N 2-acetylsulfanylethyl(trimethyl)azanium Chemical compound CC(=O)SCC[N+](C)(C)C GFFIJCYHQYHUHB-UHFFFAOYSA-N 0.000 description 2
- CKSCMRNFDBWFND-UHFFFAOYSA-N 4-hydroxy-2,3-dihydroinden-1-one Chemical compound OC1=CC=CC2=C1CCC2=O CKSCMRNFDBWFND-UHFFFAOYSA-N 0.000 description 2
- VYGIPIBKCOYHFK-UHFFFAOYSA-N 6-methoxy-2,3-dihydro-1h-inden-1-amine Chemical compound COC1=CC=C2CCC(N)C2=C1 VYGIPIBKCOYHFK-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 229940127007 Compound 39 Drugs 0.000 description 2
- 206010011953 Decreased activity Diseases 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 238000005863 Friedel-Crafts acylation reaction Methods 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 2
- 206010035039 Piloerection Diseases 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 235000010210 aluminium Nutrition 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 208000015114 central nervous system disease Diseases 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 239000002329 esterase inhibitor Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 230000006742 locomotor activity Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- YUPHAYFQAVLCRV-SECBINFHSA-N n-[(1r)-2,3-dihydro-1h-inden-1-yl]-2,2,2-trifluoroacetamide Chemical compound C1=CC=C2[C@H](NC(=O)C(F)(F)F)CCC2=C1 YUPHAYFQAVLCRV-SECBINFHSA-N 0.000 description 2
- SJDUMUAOCLZLFN-SNVBAGLBSA-N n-[(1r)-6-(2-chloroacetyl)-2,3-dihydro-1h-inden-1-yl]-2,2,2-trifluoroacetamide Chemical compound C1=C(C(=O)CCl)C=C2[C@H](NC(=O)C(F)(F)F)CCC2=C1 SJDUMUAOCLZLFN-SNVBAGLBSA-N 0.000 description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
- 229960002362 neostigmine Drugs 0.000 description 2
- LULNWZDBKTWDGK-UHFFFAOYSA-M neostigmine bromide Chemical compound [Br-].CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 LULNWZDBKTWDGK-UHFFFAOYSA-M 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 150000002923 oximes Chemical class 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000005371 pilomotor reflex Effects 0.000 description 2
- 235000015320 potassium carbonate Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- YORCIIVHUBAYBQ-UHFFFAOYSA-N propargyl bromide Chemical compound BrCC#C YORCIIVHUBAYBQ-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000005932 reductive alkylation reaction Methods 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- 210000003625 skull Anatomy 0.000 description 2
- 239000012258 stirred mixture Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 2
- 229960001685 tacrine Drugs 0.000 description 2
- UEJNEAIGIZTACB-UHFFFAOYSA-N tert-butyl n-(2,3-dihydro-1h-inden-1-yl)carbamate Chemical compound C1=CC=C2C(NC(=O)OC(C)(C)C)CCC2=C1 UEJNEAIGIZTACB-UHFFFAOYSA-N 0.000 description 2
- HWLAUUTUIGOWAB-UHFFFAOYSA-N tert-butyl n-(6-hydroxy-2,3-dihydro-1h-inden-1-yl)carbamate Chemical compound C1=C(O)C=C2C(NC(=O)OC(C)(C)C)CCC2=C1 HWLAUUTUIGOWAB-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- XJEVHMGJSYVQBQ-SECBINFHSA-N (1r)-2,3-dihydro-1h-inden-1-amine Chemical compound C1=CC=C2[C@H](N)CCC2=C1 XJEVHMGJSYVQBQ-SECBINFHSA-N 0.000 description 1
- XJEVHMGJSYVQBQ-VIFPVBQESA-N (1s)-2,3-dihydro-1h-inden-1-amine Chemical compound C1=CC=C2[C@@H](N)CCC2=C1 XJEVHMGJSYVQBQ-VIFPVBQESA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 1
- QZQSLQIZEWMPQS-UHFFFAOYSA-N (3-amino-2,3-dihydro-1h-inden-5-yl) n,n-dimethylcarbamate Chemical compound CN(C)C(=O)OC1=CC=C2CCC(N)C2=C1 QZQSLQIZEWMPQS-UHFFFAOYSA-N 0.000 description 1
- MOUPGBDOLGDVNW-SECBINFHSA-N (3r)-3-amino-2,3-dihydro-1h-inden-5-ol Chemical compound C1=C(O)C=C2[C@H](N)CCC2=C1 MOUPGBDOLGDVNW-SECBINFHSA-N 0.000 description 1
- IWYDHOAUDWTVEP-ZETCQYMHSA-N (S)-mandelic acid Chemical compound OC(=O)[C@@H](O)C1=CC=CC=C1 IWYDHOAUDWTVEP-ZETCQYMHSA-N 0.000 description 1
- GWFKPABLUSNUAP-UHFFFAOYSA-N 1-amino-2,3-dihydro-1h-inden-4-ol Chemical compound C1=CC=C(O)C2=C1C(N)CC2 GWFKPABLUSNUAP-UHFFFAOYSA-N 0.000 description 1
- RHAAGWRBIVCBSY-UHFFFAOYSA-N 2,3-dihydro-1h-inden-1-amine;hydron;chloride Chemical compound Cl.C1=CC=C2C(N)CCC2=C1 RHAAGWRBIVCBSY-UHFFFAOYSA-N 0.000 description 1
- VDSNLNUVOLTORK-UHFFFAOYSA-N 2,3-dihydro-1h-inden-1-amine;methanesulfonic acid Chemical compound CS(O)(=O)=O.C1=CC=C2C(N)CCC2=C1 VDSNLNUVOLTORK-UHFFFAOYSA-N 0.000 description 1
- NZRVARXKIQRLGQ-UHFFFAOYSA-N 2,7-dimethoxy-1,2,3,4-tetrahydronaphthalene Chemical compound C1=C(OC)C=C2CC(OC)CCC2=C1 NZRVARXKIQRLGQ-UHFFFAOYSA-N 0.000 description 1
- KCKZIWSINLBROE-UHFFFAOYSA-N 3,4-dihydro-1h-naphthalen-2-one Chemical class C1=CC=C2CC(=O)CCC2=C1 KCKZIWSINLBROE-UHFFFAOYSA-N 0.000 description 1
- VMUXSMXIQBNMGZ-UHFFFAOYSA-N 3,4-dihydrocoumarin Chemical compound C1=CC=C2OC(=O)CCC2=C1 VMUXSMXIQBNMGZ-UHFFFAOYSA-N 0.000 description 1
- PUCSCKWQTBPOPZ-UHFFFAOYSA-N 3-(dimethylamino)-2,3-dihydro-1h-inden-5-ol Chemical compound C1=C(O)C=C2C(N(C)C)CCC2=C1 PUCSCKWQTBPOPZ-UHFFFAOYSA-N 0.000 description 1
- JFEITCAAMIRLPB-UHFFFAOYSA-N 3-(ethylamino)-2,3-dihydro-1h-inden-5-ol Chemical compound C1=C(O)C=C2C(NCC)CCC2=C1 JFEITCAAMIRLPB-UHFFFAOYSA-N 0.000 description 1
- OQYUFINCFJYYFH-UHFFFAOYSA-N 3-(methylamino)-2,3-dihydro-1h-inden-5-ol Chemical compound C1=C(O)C=C2C(NC)CCC2=C1 OQYUFINCFJYYFH-UHFFFAOYSA-N 0.000 description 1
- WTRRIQCGCGCMQA-CBZIJGRNSA-N 3-Hydroxyestra-1,3,5(10),6-tetraen-17-one Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3C=CC2=C1 WTRRIQCGCGCMQA-CBZIJGRNSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- USWINTIHFQKJTR-UHFFFAOYSA-N 3-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C1=C(S(O)(=O)=O)C=C2C=C(S(O)(=O)=O)C(O)=CC2=C1 USWINTIHFQKJTR-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- CVICEEPAFUYBJG-UHFFFAOYSA-N 5-chloro-2,2-difluoro-1,3-benzodioxole Chemical group C1=C(Cl)C=C2OC(F)(F)OC2=C1 CVICEEPAFUYBJG-UHFFFAOYSA-N 0.000 description 1
- AIMITMIQEFTKGH-UHFFFAOYSA-N 6-methoxy-n-methyl-2,3-dihydro-1h-inden-1-amine Chemical compound C1=C(OC)C=C2C(NC)CCC2=C1 AIMITMIQEFTKGH-UHFFFAOYSA-N 0.000 description 1
- VIYAPIMIOKKYNF-UHFFFAOYSA-N 7-amino-5,6,7,8-tetrahydronaphthalen-2-ol Chemical compound C1=C(O)C=C2CC(N)CCC2=C1 VIYAPIMIOKKYNF-UHFFFAOYSA-N 0.000 description 1
- XEAPZXNZOJGVCZ-UHFFFAOYSA-N 7-methoxy-3,4-dihydro-1h-naphthalen-2-one Chemical compound C1CC(=O)CC2=CC(OC)=CC=C21 XEAPZXNZOJGVCZ-UHFFFAOYSA-N 0.000 description 1
- SXQYMLTXGOSXPE-UHFFFAOYSA-N 8-amino-5,6,7,8-tetrahydronaphthalen-2-ol Chemical compound C1=C(O)C=C2C(N)CCCC2=C1 SXQYMLTXGOSXPE-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- CKDWPUIZGOQOOM-UHFFFAOYSA-N Carbamyl chloride Chemical compound NC(Cl)=O CKDWPUIZGOQOOM-UHFFFAOYSA-N 0.000 description 1
- VGCXGMAHQTYDJK-UHFFFAOYSA-N Chloroacetyl chloride Chemical compound ClCC(Cl)=O VGCXGMAHQTYDJK-UHFFFAOYSA-N 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- FEWJPZIEWOKRBE-LWMBPPNESA-L D-tartrate(2-) Chemical compound [O-]C(=O)[C@@H](O)[C@H](O)C([O-])=O FEWJPZIEWOKRBE-LWMBPPNESA-L 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241001269524 Dura Species 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-L L-tartrate(2-) Chemical compound [O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-L 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 229910010084 LiAlH4 Inorganic materials 0.000 description 1
- 125000003047 N-acetyl group Chemical group 0.000 description 1
- WXNXCEHXYPACJF-ZETCQYMHSA-N N-acetyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(C)=O WXNXCEHXYPACJF-ZETCQYMHSA-N 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- MSZFSKIIVBPHBL-GFCCVEGCSA-N [(1r)-6-chloro-1-[(2,2,2-trifluoroacetyl)amino]-2,3-dihydroinden-1-yl] acetate Chemical compound C1=C(Cl)C=C2[C@@](OC(=O)C)(NC(=O)C(F)(F)F)CCC2=C1 MSZFSKIIVBPHBL-GFCCVEGCSA-N 0.000 description 1
- XRDSCFHKHGGCDR-SNVBAGLBSA-N [(3r)-3-[(2,2,2-trifluoroacetyl)amino]-2,3-dihydro-1h-inden-5-yl] 2-chloroacetate Chemical compound C1=C(OC(=O)CCl)C=C2[C@H](NC(=O)C(F)(F)F)CCC2=C1 XRDSCFHKHGGCDR-SNVBAGLBSA-N 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 229960000669 acetylleucine Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 201000008247 brain infarction Diseases 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125807 compound 37 Drugs 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229940084927 diazepam 10 mg Drugs 0.000 description 1
- DMSHWWDRAYHEBS-UHFFFAOYSA-N dihydrocoumarin Natural products C1CC(=O)OC2=C1C=C(OC)C(OC)=C2 DMSHWWDRAYHEBS-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- OAMZXMDZZWGPMH-UHFFFAOYSA-N ethyl acetate;toluene Chemical compound CCOC(C)=O.CC1=CC=CC=C1 OAMZXMDZZWGPMH-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 150000004820 halides Chemical group 0.000 description 1
- 229960003878 haloperidol Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 208000016290 incoordination Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- QNXSIUBBGPHDDE-UHFFFAOYSA-N indan-1-one Chemical class C1=CC=C2C(=O)CCC2=C1 QNXSIUBBGPHDDE-UHFFFAOYSA-N 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000027905 limb weakness Diseases 0.000 description 1
- 231100000861 limb weakness Toxicity 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 210000004373 mandible Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- PIPAJLPNWZMYQA-YVSFHVDLSA-N methylatropine Chemical compound C[N+]1(C)[C@@H]2CC[C@H]1C[C@@H](C2)OC(=O)[C@@H](CO)c3ccccc3 PIPAJLPNWZMYQA-YVSFHVDLSA-N 0.000 description 1
- 229960005096 methylatropine Drugs 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 210000003657 middle cerebral artery Anatomy 0.000 description 1
- 230000009525 mild injury Effects 0.000 description 1
- 230000009526 moderate injury Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003562 morphometric effect Effects 0.000 description 1
- 238000013425 morphometry Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- 230000004973 motor coordination Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- VNAXXPBYEKLMMP-UHFFFAOYSA-N o-[(3-amino-2,3-dihydro-1h-inden-5-yl)] n,n-dimethylcarbamothioate Chemical compound CN(C)C(=S)OC1=CC=C2CCC(N)C2=C1 VNAXXPBYEKLMMP-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000002475 olfactory pathway Anatomy 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 208000018299 prostration Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000005245 right atrium Anatomy 0.000 description 1
- 230000028527 righting reflex Effects 0.000 description 1
- 230000009183 running Effects 0.000 description 1
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 208000037974 severe injury Diseases 0.000 description 1
- 230000009528 severe injury Effects 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 210000000966 temporal muscle Anatomy 0.000 description 1
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 150000003558 thiocarbamic acid derivatives Chemical class 0.000 description 1
- AWLILQARPMWUHA-UHFFFAOYSA-M thiopental sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC([S-])=NC1=O AWLILQARPMWUHA-UHFFFAOYSA-M 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 230000009184 walking Effects 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
- C07C271/56—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/24—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
- C07C271/42—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/44—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
- C07C271/58—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C333/00—Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C333/02—Monothiocarbamic acids; Derivatives thereof
- C07C333/04—Monothiocarbamic acids; Derivatives thereof having nitrogen atoms of thiocarbamic groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Centrifugal Separators (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL119853 | 1996-12-18 | ||
| IL11985396A IL119853A0 (en) | 1996-12-18 | 1996-12-18 | Aminoindan derivatives |
| IL120510 | 1997-03-24 | ||
| IL12051097A IL120510A0 (en) | 1997-03-24 | 1997-03-24 | Phenylethylamine derivatives |
| PCT/US1997/024155 WO1998027055A1 (en) | 1996-12-18 | 1997-12-18 | Aminoindan derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2275425A1 CA2275425A1 (en) | 1998-06-25 |
| CA2275425C true CA2275425C (en) | 2009-08-04 |
Family
ID=26323338
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002275425A Expired - Lifetime CA2275425C (en) | 1996-12-18 | 1997-12-18 | Aminoindan derivatives |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US6303650B1 (enExample) |
| EP (2) | EP0966435B1 (enExample) |
| JP (1) | JP4222632B2 (enExample) |
| AT (2) | ATE377585T1 (enExample) |
| AU (1) | AU5726898A (enExample) |
| CA (1) | CA2275425C (enExample) |
| DE (2) | DE69738275T2 (enExample) |
| DK (1) | DK0966435T3 (enExample) |
| ES (1) | ES2241064T3 (enExample) |
| HU (1) | HU229507B1 (enExample) |
| IL (1) | IL130528A (enExample) |
| PT (1) | PT966435E (enExample) |
| WO (1) | WO1998027055A1 (enExample) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE377585T1 (de) * | 1996-12-18 | 2007-11-15 | Teva Pharma | Aminoindanderivate |
| DE69921815T2 (de) * | 1998-06-03 | 2005-11-10 | Nissan Chemical Industries, Ltd. | Indanderivate |
| JP2003512426A (ja) | 1999-10-27 | 2003-04-02 | テバ ファーマシューティカル インダストリーズ リミティド | 双極性気分障害における躁病の治療のための１−アミノインダンの使用。 |
| WO2003072055A2 (en) * | 2002-02-27 | 2003-09-04 | Teva Pharmaceutical Industries, Ltd. | Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective mao inhibitors |
| US20040010038A1 (en) * | 2002-02-27 | 2004-01-15 | Eran Blaugrund | Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors |
| JP4757024B2 (ja) * | 2002-11-07 | 2011-08-24 | テクニオン リサーチ アンド ディベラップメント ファウンデイション リミテッド | 神経保護鉄キレート剤及びそれを含む医薬組成物 |
| CA2547053C (en) | 2003-11-25 | 2014-05-27 | Technion Research & Development Foundation Ltd. | Compositions and methods for treatment of cardiovascular disorders and diseases |
| US8097608B2 (en) | 2003-11-25 | 2012-01-17 | Technion Research And Development Foundation Ltd. | Methods for treatment of cardiovascular disorders and diseases |
| JP2005232148A (ja) * | 2004-02-03 | 2005-09-02 | Technion Research & Development Foundation Ltd | 神経保護剤としてプロパルギルアミンの使用 |
| EP1574498A1 (en) | 2004-02-19 | 2005-09-14 | PPG-Sipsy | Process for the synthesis of substituted alpha-aminoindan derivatives |
| EP1778196A4 (en) * | 2004-07-26 | 2008-12-17 | Teva Pharma | PHARMACEUTICAL DOSAGES CONTAINING RASAGILINE |
| WO2006014968A2 (en) * | 2004-07-27 | 2006-02-09 | Teva Pharmaceutical Industries, Ltd. | Propargyl nitroxydes and indanyl nitroxides and their use for the treatment of neurologic diseases and disorders |
| US7262326B2 (en) | 2004-09-08 | 2007-08-28 | Teva Pharmaceuticals Industries Ltd. | Process for the synthesis of indanylamine or aminotetralin derivatives and novel intermediates |
| ES2420404T3 (es) * | 2005-02-17 | 2013-08-23 | Teva Pharmaceutical Industries Ltd. | Terapia de combinación con acetato de glatiramero y rasagilina para el tratamiento de esclerosis múltiple |
| EP1851188A1 (en) | 2005-02-22 | 2007-11-07 | Teva Pharmaceutical Industries Limited | Improved process for the synthesis of enantiomeric indanylamine derivatives |
| AU2006216696B2 (en) | 2005-02-23 | 2011-08-18 | Teva Pharmaceutical Industries, Ltd. | Rasagiline formulations of improved content uniformity |
| JP2008531571A (ja) * | 2005-02-24 | 2008-08-14 | テバ ファーマシューティカル インダストリーズ リミティド | 酒石酸ラドスチジルの結晶、その製造方法、および医薬組成物 |
| WO2006091836A1 (en) | 2005-02-24 | 2006-08-31 | Teva Pharmaceutical Industries, Ltd. | Formulations of ladostigil tartrate |
| WO2006130726A2 (en) * | 2005-06-01 | 2006-12-07 | Teva Pharmaceutical Industries, Ltd. | Use of ladostigil for the treatment of multiple sclerosis |
| NZ564130A (en) * | 2005-06-02 | 2009-12-24 | Jenrin Discovery | N-propargyl-1-aminoindan compounds useful for treating obesity |
| US7539261B2 (en) * | 2005-08-22 | 2009-05-26 | Nec Laboratories America, Inc. | Multi-layer coded modulation for non-ergodic block fading channels |
| US20070088082A1 (en) * | 2005-09-28 | 2007-04-19 | Judith Aronhime | Polymorphic forms of ladostigil tartrate |
| WO2007038677A2 (en) * | 2005-09-28 | 2007-04-05 | Teva Pharmaceutical Industries Ltd. | Methods for preparation of ladostigil tartrate crystalline form a1 |
| US8263655B2 (en) * | 2005-10-06 | 2012-09-11 | Technion Research And Development Foundation Ltd | Methods for treatment of renal failure |
| US20070238893A1 (en) * | 2005-11-04 | 2007-10-11 | Lee Boulton | Asymmetric hydrogenation of acyl enamides |
| US20070238895A1 (en) * | 2005-11-07 | 2007-10-11 | Lee Boulton | N-protected aminoindanes and methods of their preparation |
| JP2009521402A (ja) * | 2005-11-17 | 2009-06-04 | テバ ファーマシューティカル インダストリーズ リミティド | プロパルギル化アミノインダンの分離のための方法 |
| US7572834B1 (en) | 2005-12-06 | 2009-08-11 | Teva Pharmaceutical Industries, Ltd. | Rasagiline formulations and processes for their preparation |
| AU2006326642B2 (en) * | 2005-12-09 | 2012-05-03 | Technion Research And Development Foundation Ltd. | Use of low-dose ladostigil for neuroprotection |
| US20070135518A1 (en) * | 2005-12-09 | 2007-06-14 | Marta Weinstock-Rosin | Use of low-dose ladostigil for neuroprotection |
| EP1991214B1 (en) | 2006-02-21 | 2015-08-05 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of multiple system atrophy |
| TW200744576A (en) | 2006-02-24 | 2007-12-16 | Teva Pharma | Propargylated aminoindans, processes for preparation, and uses thereof |
| US20070232691A1 (en) * | 2006-03-31 | 2007-10-04 | Tamar Goren | Use of ladostigil for the treatment of schizophrenia |
| US8946300B2 (en) | 2006-04-03 | 2015-02-03 | Teva Pharmaceutical Industries, Ltd. | Use of rasagilline for the treatment of restless legs syndrome |
| EP1892233A1 (de) * | 2006-08-18 | 2008-02-27 | Ratiopharm GmbH | Neue Salze des Wirkstoffs Rasagilin |
| ATE528989T1 (de) * | 2006-12-14 | 2011-11-15 | Teva Pharma | Kristalline feste rasagilin-base |
| US7547806B2 (en) | 2006-12-14 | 2009-06-16 | Teva Pharmaceutical Industries, Ltd. | Tannate salt of rasagiline |
| EP1987816A1 (de) * | 2007-04-30 | 2008-11-05 | Ratiopharm GmbH | Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff |
| US8188149B2 (en) * | 2007-09-17 | 2012-05-29 | Teva Pharmaceutical Industries, Ltd. | Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss |
| NZ586025A (en) * | 2008-01-11 | 2012-08-31 | Teva Pharma | Rasagiline mesylate tablet coated with a composisiton comprising methacrylic acid - ethyl acrylate copolymer and triethyl citrate |
| WO2009151594A1 (en) * | 2008-06-10 | 2009-12-17 | Teva Pharmaceutical Industries, Ltd. | Rasagiline soft gelatin capsules |
| JP2011522892A (ja) * | 2008-06-13 | 2011-08-04 | テバ ファーマシューティカル インダストリーズ リミティド | パーキンソン病緩和のためのラサギリン |
| JP2011525489A (ja) * | 2008-06-19 | 2011-09-22 | テバ ファーマシューティカル インダストリーズ リミティド | ラサリジン塩基の精製方法 |
| EP2299992A4 (en) | 2008-06-19 | 2015-10-21 | Teva Pharma | PROCESS FOR THE PREPARATION AND DRYING OF A SOLID RASAGILINE BASE |
| US20100189788A1 (en) * | 2009-01-23 | 2010-07-29 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline base formulation |
| HRP20140845T1 (hr) | 2009-07-09 | 2014-11-07 | Ratiopharm Gmbh | Soli rasagilina i farmaceutski pripravci od njih |
| US9943489B2 (en) | 2010-02-03 | 2018-04-17 | Pharmatwob Ltd. | Extended release formulations of rasagiline and uses thereof |
| RU2013108256A (ru) | 2010-07-27 | 2014-09-10 | Тева Фармасьютикал Индастриз Лтд. | Дисперсии цитрата разагилина |
| RU2587330C2 (ru) | 2010-07-27 | 2016-06-20 | Тева Фармасьютикал Индастриз Лтд. | Применение разагилина для лечения обонятельной дисфункции |
| US9339469B2 (en) | 2011-10-10 | 2016-05-17 | Teva Pharmaceutical Industries, Ltd. | R(+)-N-methyl-propargyl-aminoindan |
| EA201490761A1 (ru) | 2011-10-10 | 2014-11-28 | Тева Фармасьютикал Индастриз Лтд. | R(+)-n-формилпропаргиламиноиндан |
| CN104379142B (zh) * | 2012-02-12 | 2018-02-13 | 耶路撒冷希伯来大学伊森姆研究发展有限公司 | 用于免疫调节的拉多替吉治疗 |
| JP2015529196A (ja) | 2012-08-17 | 2015-10-05 | テバ ファーマシューティカル インダストリーズ リミティド | ラサギリンの非経口製剤 |
| CN121001985A (zh) * | 2023-03-31 | 2025-11-21 | 三井化学株式会社 | 氨基甲酸酯化合物 |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3201470A (en) | 1965-08-17 | Chsx c cech | ||
| US2916490A (en) | 1959-12-08 | Ocjhs | ||
| US2982783A (en) | 1961-05-02 | Amevoevdanes | ||
| US3123642A (en) | 1964-03-03 | Indanyl and tetrahydronaphthyl | ||
| SE371190B (enExample) | 1972-03-24 | 1974-11-11 | Kabi Ab | |
| US2573645A (en) | 1949-05-25 | 1951-10-30 | Smith Kline French Lab | N-hydroxyethyl aminoindanes |
| GB852735A (en) | 1956-04-13 | 1960-11-02 | Schering Ag | Manufacture of 1-aminoindanes |
| US3060091A (en) | 1961-02-13 | 1962-10-23 | Ciba Geigy Corp | Analgesic composition consisting of morphines and amino-indanes |
| US3178478A (en) | 1961-02-13 | 1965-04-13 | Ciba Geigy Corp | 2-amino-5-halo-indanes |
| US3253037A (en) | 1962-06-19 | 1966-05-24 | Ciba Geigy Corp | N-2-alkynyl-amino-benzocylo-alkanes |
| GB1187017A (en) | 1966-07-16 | 1970-04-08 | Aspro Nicholas Ltd | Substituted 1-Amino Indanes and Tetrahydronaphthalens |
| US3709996A (en) | 1963-08-02 | 1973-01-09 | Aspro Nicholas Ltd | Pharmaceutical compositions containing n-cyclopropyl-1-aminoindane compounds and adapted for administration to obtain inhibition of monoamine oxidase enzyme and process |
| NL6408165A (enExample) | 1964-07-17 | 1966-01-18 | ||
| US3308157A (en) | 1964-08-07 | 1967-03-07 | Colgate Palmolive Co | N-(benzocyclobutene-1-loweralkyl)-carboxylic acid amides |
| US3637740A (en) | 1969-04-21 | 1972-01-25 | Pfizer | Aminobenzocycloalkane compounds |
| US3507962A (en) | 1969-05-09 | 1970-04-21 | Thompson Chem Co Hayward | Controlling leafminer insects with selected carbamate insecticides,including 3,5-dimethyl-4-dimethylamino-methyl phenyl-n-methylcarbamate |
| US3704323A (en) | 1969-12-23 | 1972-11-28 | Squibb & Sons Inc | Indane derivatives |
| NL7011683A (enExample) | 1970-08-07 | 1972-02-09 | ||
| US3991207A (en) | 1971-03-18 | 1976-11-09 | Pfizer Inc. | Combination therapy for Parkinson's disease |
| US3751420A (en) | 1971-04-01 | 1973-08-07 | Squibb & Sons Inc | Monoolmonoene amines |
| BE786748A (fr) | 1971-07-26 | 1973-01-26 | Basf Ag | 1-aminomethyl-indanes-n-substitues |
| US4029731A (en) | 1974-11-06 | 1977-06-14 | Pfizer Inc. | Aminophenyltetralin compounds |
| US4134997A (en) | 1977-03-01 | 1979-01-16 | University Of Iowa Research Foundation | Effect of an aminotetralin derivative on coronary blood flow in infarcted hearts |
| US4096173A (en) | 1977-03-28 | 1978-06-20 | Eli Lilly And Company | Chlorinated 1-aminoindane N-methyl transferase inhibitors |
| US4128666A (en) | 1977-08-18 | 1978-12-05 | Smithkline Corporation | 4 AND 5-Halo substituted 2-indanamine compounds |
| US4132737A (en) | 1978-02-27 | 1979-01-02 | Eli Lilly And Company | Trifluoromethyl substituted 1-aminoindanes |
| US5286747A (en) | 1981-05-08 | 1994-02-15 | Per A. E. Carlsson | 1-alkyl-2-aminotetralin derivatives |
| DE3407842A1 (de) | 1983-03-04 | 1984-09-06 | Otsuka Pharmaceutical Co. Ltd., Tokyo | Indanderivate und deren salze, verfahren zu deren herstellung und arzneimittel und antioxidationsmittel, welche diese enthalten |
| US4529723A (en) | 1983-04-29 | 1985-07-16 | William H. Rorer, Inc. | Bicyclic benzenoid aminoalkylene ethers and thioethers, pharmaceutical compositions and use |
| US5242919A (en) | 1984-08-31 | 1993-09-07 | Otsuka Pharmaceutical Co., Ltd. | 2,3-dihydro-1H-indene derivatives |
| JPS6169747A (ja) | 1984-08-31 | 1986-04-10 | Otsuka Pharmaceut Co Ltd | ２，３―ジヒドロ―１ｈ―インデン誘導体及びその製造法 |
| US5378729A (en) | 1985-02-15 | 1995-01-03 | Research Corporation Technologies, Inc. | Amino acid derivative anticonvulsant |
| US5654301A (en) | 1985-02-15 | 1997-08-05 | Research Corporation Technologies, Inc. | Amino acid derivative anticonvulsant |
| IL74497A (en) | 1985-03-05 | 1990-02-09 | Proterra Ag | Pharmaceutical compositions containing phenyl carbamate derivatives and certain phenyl carbamate derivatives |
| US4632939A (en) | 1985-03-15 | 1986-12-30 | Eli Lilly And Company | Anticonvulsant agents |
| US4833273A (en) | 1986-02-03 | 1989-05-23 | Warner-Lambert Company | Process for the resolution of 1-aminoindanes |
| DE252290T1 (de) | 1986-06-10 | 1988-06-09 | Chiesi Farmaceutici S.P.A., Parma | Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen. |
| US5153225A (en) | 1986-12-10 | 1992-10-06 | Bayer Aktiengesellschaft | Substituted basic 2-aminotetralin in pharmaceuticals |
| HU201906B (en) | 1987-03-04 | 1991-01-28 | Sandoz Ag | Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them |
| US5011995A (en) | 1987-07-28 | 1991-04-30 | Ciba-Geigy Corporation | Process for the preparation of optically active secondary amines |
| US4873241A (en) | 1988-10-31 | 1989-10-10 | Fisons Corporation | 2-amino-N-(2-phenylindan-2-yl)acetamides useful as anti-epileptics |
| US5225596A (en) | 1989-01-09 | 1993-07-06 | The Upjohn Company | Halo substituted aminotetralins |
| CA1335106C (en) | 1989-02-27 | 1995-04-04 | John Mehnert Schaus | Ring-substituted 2-amino-1,2,3,4-tetra-hydronaphthalenes |
| JP2725378B2 (ja) * | 1989-05-29 | 1998-03-11 | 武田薬品工業株式会社 | カルバミド酸エステル誘導体 |
| IE902294A1 (en) | 1989-07-06 | 1991-01-16 | Abbott Lab | Alkynyl amines that regulate cholinergic neurotransmission |
| US5118704A (en) | 1989-08-30 | 1992-06-02 | Whitby Research, Inc. | Substituted 2-aminotetralins useful as dopaminergics |
| US5071875A (en) | 1989-09-25 | 1991-12-10 | Northwestern University | Substituted 2-amidotetralins as melatonin agonists and antagonists |
| FR2654104B1 (fr) | 1989-11-07 | 1992-01-03 | Adir | Nouveaux derives du 1,2-benzisoxazole, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent. |
| JPH03176457A (ja) | 1989-12-04 | 1991-07-31 | Nippon Paint Co Ltd | 新規プロパルギル化合物、その製法ならびに該化合物を含む被覆材 |
| IL92952A (en) | 1990-01-03 | 1994-06-24 | Teva Pharma | R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them |
| FR2662162B1 (fr) | 1990-05-18 | 1995-01-20 | Adir | Nouveaux derives de l'amino piperidine, de l'amino pyrrolidine et de l'amino perhydroazepine, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent. |
| TW197435B (enExample) | 1990-11-22 | 1993-01-01 | Takeda Pharm Industry Co Ltd | |
| IL99759A (en) | 1991-10-16 | 1997-06-10 | Teva Pharma | Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them |
| PT664291E (pt) | 1992-10-05 | 2000-11-30 | Ube Industries | Composto de pirimidina |
| US5350762A (en) | 1993-03-08 | 1994-09-27 | Hoechst-Roussel Pharmaceuticals Incorporated | Tetrahydrocyclopent[B]indole methanamines and related compounds |
| GB9315600D0 (en) | 1993-07-28 | 1993-09-08 | Smithkline Beecham Plc | Compounds |
| JP3342491B2 (ja) | 1993-08-06 | 2002-11-11 | ファルマシア・アンド・アップジョン・カンパニー | 選択的ドーパミンｄ３リガンドとしての２−アミノインダン類 |
| US5516943A (en) | 1993-09-14 | 1996-05-14 | Sepracor, Inc. | Process for preparing cyclic CIS-1-amino-2-alkanols |
| US5401758A (en) | 1993-10-07 | 1995-03-28 | Bristol-Myers Squibb Company | Pyridinyl cyanoguanidine compounds |
| IL111240A (en) | 1993-10-18 | 2001-10-31 | Teva Pharma | Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them |
| US5877218A (en) | 1994-01-10 | 1999-03-02 | Teva Pharmaceutical Industries, Ltd. | Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives |
| HU225986B1 (en) * | 1994-01-10 | 2008-02-28 | Teva Pharma | Use of 1-aminoindan derivatives for preparing pharmaceutical compns. and 1-aminoindan derivatives |
| FR2717175B1 (fr) | 1994-03-11 | 1996-06-14 | Adir | Nouveaux composés alkylaminoindanes, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent. |
| IT1271679B (it) | 1994-07-18 | 1997-06-04 | Mediolanum Farmaceutici Srl | Derivati del fenilcarbammato atti all'impiego come anticolinesterasici |
| US5646188A (en) | 1995-07-05 | 1997-07-08 | Teva Pharmaceutical Industries, Ltd. | Polyamine derivatives of 1-aminoindan |
| ATE377585T1 (de) * | 1996-12-18 | 2007-11-15 | Teva Pharma | Aminoindanderivate |
| US6251938B1 (en) | 1996-12-18 | 2001-06-26 | Teva Pharmaceutical Industries, Ltd., | Phenylethylamine derivatives |
| JP3002155B2 (ja) | 1997-06-25 | 2000-01-24 | 日本サーボ株式会社 | 景品懸吊装置 |
| US20040010038A1 (en) | 2002-02-27 | 2004-01-15 | Eran Blaugrund | Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors |
-
1997
- 1997-12-18 AT AT05002578T patent/ATE377585T1/de not_active IP Right Cessation
- 1997-12-18 PT PT97953541T patent/PT966435E/pt unknown
- 1997-12-18 ES ES97953541T patent/ES2241064T3/es not_active Expired - Lifetime
- 1997-12-18 AU AU57268/98A patent/AU5726898A/en not_active Abandoned
- 1997-12-18 IL IL13052897A patent/IL130528A/en not_active IP Right Cessation
- 1997-12-18 DK DK97953541T patent/DK0966435T3/da active
- 1997-12-18 EP EP97953541A patent/EP0966435B1/en not_active Expired - Lifetime
- 1997-12-18 AT AT97953541T patent/ATE292619T1/de not_active IP Right Cessation
- 1997-12-18 DE DE69738275T patent/DE69738275T2/de not_active Expired - Lifetime
- 1997-12-18 WO PCT/US1997/024155 patent/WO1998027055A1/en not_active Ceased
- 1997-12-18 JP JP52804898A patent/JP4222632B2/ja not_active Expired - Fee Related
- 1997-12-18 CA CA002275425A patent/CA2275425C/en not_active Expired - Lifetime
- 1997-12-18 DE DE69732984T patent/DE69732984T2/de not_active Expired - Lifetime
- 1997-12-18 HU HU0101130A patent/HU229507B1/hu unknown
- 1997-12-18 EP EP05002578A patent/EP1535902B1/en not_active Expired - Lifetime
-
1999
- 1999-06-18 US US09/336,493 patent/US6303650B1/en not_active Expired - Lifetime
-
2001
- 2001-08-31 US US09/944,850 patent/US6462222B1/en not_active Expired - Lifetime
- 2001-08-31 US US09/944,912 patent/US6538025B2/en not_active Ceased
-
2005
- 2005-03-25 US US11/091,008 patent/USRE39616E1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP4222632B2 (ja) | 2009-02-12 |
| EP1535902B1 (en) | 2007-11-07 |
| US6303650B1 (en) | 2001-10-16 |
| US6538025B2 (en) | 2003-03-25 |
| CA2275425A1 (en) | 1998-06-25 |
| PT966435E (pt) | 2005-06-30 |
| DE69738275D1 (de) | 2007-12-20 |
| DE69732984D1 (de) | 2005-05-12 |
| WO1998027055A1 (en) | 1998-06-25 |
| DK0966435T3 (da) | 2005-08-15 |
| EP1535902A1 (en) | 2005-06-01 |
| IL130528A (en) | 2004-12-15 |
| ATE377585T1 (de) | 2007-11-15 |
| USRE39616E1 (en) | 2007-05-08 |
| HK1024462A1 (en) | 2000-10-13 |
| HU229507B1 (en) | 2014-01-28 |
| JP2001506269A (ja) | 2001-05-15 |
| EP0966435B1 (en) | 2005-04-06 |
| AU5726898A (en) | 1998-07-15 |
| HK1076098A1 (en) | 2006-01-06 |
| US20020188020A1 (en) | 2002-12-12 |
| ES2241064T3 (es) | 2005-10-16 |
| US6462222B1 (en) | 2002-10-08 |
| HUP0101130A3 (en) | 2003-02-28 |
| HUP0101130A2 (hu) | 2001-08-28 |
| DE69738275T2 (de) | 2008-08-28 |
| EP0966435A1 (en) | 1999-12-29 |
| DE69732984T2 (de) | 2006-02-16 |
| ATE292619T1 (de) | 2005-04-15 |
| EP0966435A4 (en) | 2003-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2275425C (en) | Aminoindan derivatives | |
| US6251938B1 (en) | Phenylethylamine derivatives | |
| US6271263B1 (en) | Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives | |
| US20040010038A1 (en) | Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors | |
| JPH09501918A (ja) | 酸化窒素合成酵素活性を有するアミジン誘導体 | |
| WO1996021640A1 (en) | Optically active aminoindane derivatives and preparation thereof | |
| CA2519061A1 (en) | Substituted aniline derivatives | |
| EP0951284B1 (en) | Phenylethylamine derivatives | |
| CA2477218A1 (en) | Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective mao inhibitors | |
| SK162795A3 (en) | N-substituted azaheterocyclic carboxylic acids and esters thereof, preparation method thereof and pharmaceutical compositions containing them | |
| HK1076098B (en) | Aminoindan derivatives | |
| HK1024462B (en) | Aminoindan derivatives | |
| HK1022838B (en) | Phenylethylamine derivatives | |
| IL130527A (en) | Phenylethylamine derivatives and pharmaceutical compositions containing them |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20171218 |